Published in Neurol Sci on May 01, 2014
Emerging treatments for the primary headache disorders. Neurol Sci (2015) 0.75
Resting-state fMRI study of acute migraine treatment with kinetic oscillation stimulation in nasal cavity. Neuroimage Clin (2016) 0.75
Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet (2001) 6.61
Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology (2013) 4.83
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med (2004) 4.39
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology (2007) 3.43
Satellite glial cells in sensory ganglia: from form to function. Brain Res Brain Res Rev (2005) 3.12
The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol (1993) 3.07
Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol (2010) 2.70
Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology (2009) 2.40
Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia (2012) 2.38
Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache (2007) 2.36
Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol (2004) 2.36
Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol (2006) 2.23
Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia (2010) 2.17
A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache (2012) 2.15
BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia (2013) 2.14
Occipital nerve stimulation for chronic headache--long-term safety and efficacy. Cephalalgia (2007) 1.91
Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia (1996) 1.69
Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial. Cephalalgia (2010) 1.67
Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol (2004) 1.65
Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache (2013) 1.65
Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia (2010) 1.63
The effect of vagus nerve stimulation on migraines. J Pain (2003) 1.60
Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia (2010) 1.58
Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain (2003) 1.58
Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med (2006) 1.53
Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia (2013) 1.52
Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs (2007) 1.45
The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol (2006) 1.43
The epidemiology of primary headache disorders. Semin Neurol (2010) 1.36
Safety and patients' satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain (2013) 1.26
Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol (2004) 1.25
Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain (2009) 1.24
Triptans for the management of migraine. Drugs (2010) 1.24
Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia (2005) 1.21
Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience (2010) 1.15
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia (2011) 1.13
BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia (2010) 1.01
Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain (2004) 1.00
Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst (1999) 0.99
Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology (2011) 0.98
Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides (1998) 0.97
MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache (2011) 0.96
Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study. Cephalalgia (2010) 0.96
Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. Headache (2007) 0.96
Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: preliminary data. Neurol Sci (2009) 0.94
Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci (2006) 0.93
Zelrix: a novel transdermal formulation of sumatriptan. Headache (2009) 0.92
Can vagus nerve stimulation help migraine? Cephalalgia (2008) 0.91
A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res (2007) 0.89
A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache (2009) 0.88
Vagal nerve stimulation aborts migraine in patient with intractable epilepsy. Cephalalgia (2002) 0.87
Antimigraine efficacy of telcagepant based on patient's historical triptan response. Headache (2010) 0.85
Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol (2009) 0.85
New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors. Curr Treat Options Neurol (2012) 0.84
Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia (2006) 0.84
Transcranial magnetic stimulation for migraine: clinical effects. J Headache Pain (2006) 0.83
Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia (2013) 0.83
Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia (2010) 0.83
Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache (2009) 0.83
Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache (2012) 0.83
Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol (2010) 0.83
Intranasal civamide for the acute treatment of migraine headache. Cephalalgia (2000) 0.82
Clinical implications for breath-powered powder sumatriptan intranasal treatment. Headache (2013) 0.81
Intranasal civamide for the treatment of episodic cluster headaches. Arch Neurol (2002) 0.81
Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache (2011) 0.81
Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache (2011) 0.80
The therapeutic future in headache. Neurol Sci (2012) 0.80
Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. Headache (2011) 0.80
Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. Neuropsychiatr Dis Treat (2012) 0.80
Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache (2010) 0.80
Breath powered nasal delivery: a new route to rapid headache relief. Headache (2013) 0.79
Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia (2010) 0.79
A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract (2000) 0.78
The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol (2011) 0.77
Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache (2012) 0.77
The pipeline in headache therapy. CNS Drugs (2013) 0.77
5-HT(1F) Receptor agonists: a new treatment option for migraine attacks? Neurotherapeutics (2010) 0.76
MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine. Expert Opin Pharmacother (2012) 0.76
Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. Curr Med Res Opin (2011) 0.75
An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan. Headache (2012) 0.75
Migraine and obesity: epidemiology, mechanisms, and implications. Headache (2009) 2.05
The effect of weather on headache. Headache (2004) 1.87
Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache (2013) 1.65
Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache (2003) 1.53
The Global Campaign (GC) to Reduce the Burden of Headache Worldwide. The International Team for Specialist Education (ITSE). J Headache Pain (2005) 1.52
New migraine preventive options: an update with pathophysiological considerations. Rev Hosp Clin Fac Med Sao Paulo (2003) 1.41
Obesity and migraine: the effect of age, gender and adipose tissue distribution. Headache (2009) 1.32
Triptans for the management of migraine. Drugs (2010) 1.24
Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache (2006) 1.16
Chronic daily headache: correlation between the 2004 and the 1988 International Headache Society diagnostic criteria. Headache (2004) 1.08
Comment on: "Headaches during war: analysis of presentation, treatment, and factors associated with outcome". Cephalalgia (2012) 1.07
Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol (2002) 1.03
Chronic daily headache: identification of factors associated with induction and transformation. Headache (2002) 1.00
Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache (2004) 0.97
The association of obesity with episodic and chronic migraine. Headache (2012) 0.96
Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs (2004) 0.93
Assessment of adverse events associated with triptans--methods of assessment influence the results. Headache (2004) 0.91
Tinnitus in migraine: an allodynic symptom secondary to abnormal cortical functioning? Headache (2005) 0.90
Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache (2004) 0.89
Sumatriptan: a decade of use and experience in the treatment of migraine. Expert Rev Neurother (2004) 0.88
The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache (2007) 0.87
Zolmitriptan nasal spray in the acute treatment of cluster headache: a meta-analysis of two studies. Headache (2009) 0.86
Role of antiepileptic drugs as preventive agents for migraine. CNS Drugs (2010) 0.86
Obesity and chronic daily headache. Curr Pain Headache Rep (2012) 0.85
Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification. J Headache Pain (2009) 0.85
Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. Expert Opin Drug Metab Toxicol (2007) 0.84
New drug delivery options for migraine. Expert Rev Neurother (2011) 0.82
Ten years of rizatriptan: from development to clinical science and future directions. Headache (2009) 0.82
Role of melatonin in the pathophysiology of migraine: implications for treatment. CNS Drugs (2006) 0.82
Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care. Headache (2003) 0.82
High-altitude headache. Curr Pain Headache Rep (2007) 0.81
Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache (2007) 0.81
Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. Neuropsychiatr Dis Treat (2012) 0.80
Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions. Headache (2014) 0.80
Update on future headache treatments. Neurol Sci (2013) 0.80
Intranasal zolmitriptan for the treatment of acute migraine. Headache (2013) 0.79
Hemicrania continua: a report of ten new cases. Arq Neuropsiquiatr (2002) 0.78
Why does vomiting stop a migraine attack? Curr Pain Headache Rep (2013) 0.77
Prophylactic migraine therapy: emerging treatment options. Curr Pain Headache Rep (2004) 0.77
The pipeline in headache therapy. CNS Drugs (2013) 0.77
Chronic daily headache in adolescents: an 8-year follow-up study. Neurology (2010) 0.76
New and emerging treatments for headache. Expert Rev Neurother (2012) 0.76
New developments in migraine prophylaxis. Expert Opin Pharmacother (2003) 0.75
Emerging treatments for the primary headache disorders. Neurol Sci (2015) 0.75
Acute and preventive pharmacologic treatment of cluster headache. Neurology (2011) 0.75
Analgesic use: a predictor of chronic pain in medication overuse headache: the Head-HUNT study. Neurology (2004) 0.75
The vasodilatory activity of CGRP: a response. Headache (2014) 0.75
Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Pain Manag (2014) 0.75
Parsing the migraine attack. Headache (2013) 0.75
Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study. Headache (2005) 0.75
Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review. Clin Neuropharmacol (2017) 0.75
A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine. Neurol Sci (2013) 0.75
Advances in the pharmacologic treatment of tension-type headache. Curr Pain Headache Rep (2008) 0.75
The next two years. Cephalalgia (2013) 0.75
Ethical considerations in cluster headache research. Curr Pain Headache Rep (2002) 0.75